These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16585454)

  • 1. Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex.
    Marenco S; Steele SU; Egan MF; Goldberg TE; Straub RE; Sharrief AZ; Weinberger DR
    Am J Psychiatry; 2006 Apr; 163(4):740-2. PubMed ID: 16585454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate levels and neurocognition in non-smoking, active alcoholics.
    Xia Y; Ma D; Hu J; Tang C; Wu Z; Liu L; Xin F
    Behav Brain Funct; 2012 Aug; 8():42. PubMed ID: 22909248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia.
    Egan MF; Straub RE; Goldberg TE; Yakub I; Callicott JH; Hariri AR; Mattay VS; Bertolino A; Hyde TM; Shannon-Weickert C; Akil M; Crook J; Vakkalanka RK; Balkissoon R; Gibbs RA; Kleinman JE; Weinberger DR
    Proc Natl Acad Sci U S A; 2004 Aug; 101(34):12604-9. PubMed ID: 15310849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Working memory deficits and levels of N-acetylaspartate in patients with schizophreniform disorder.
    Bertolino A; Sciota D; Brudaglio F; Altamura M; Blasi G; Bellomo A; Antonucci N; Callicott JH; Goldberg TE; Scarabino T; Weinberger DR; Nardini M
    Am J Psychiatry; 2003 Mar; 160(3):483-9. PubMed ID: 12611829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia.
    Callicott JH; Bertolino A; Egan MF; Mattay VS; Langheim FJ; Weinberger DR
    Am J Psychiatry; 2000 Oct; 157(10):1646-51. PubMed ID: 11007719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP.
    Sartorius LJ; Weinberger DR; Hyde TM; Harrison PJ; Kleinman JE; Lipska BK
    Neuropsychopharmacology; 2008 Oct; 33(11):2626-34. PubMed ID: 18256595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia.
    Bertolino A; Esposito G; Callicott JH; Mattay VS; Van Horn JD; Frank JA; Berman KF; Weinberger DR
    Am J Psychiatry; 2000 Jan; 157(1):26-33. PubMed ID: 10618009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report.
    Delamillieure P; Fernandez J; Constans JM; Brazo P; Benali K; Abadie P; Vasse T; Thibaut F; Courthéoux P; Petit M; Dollfus S
    Am J Psychiatry; 2000 Apr; 157(4):641-3. PubMed ID: 10739430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus.
    Yoo SY; Yeon S; Choi CH; Kang DH; Lee JM; Shin NY; Jung WH; Choi JS; Jang DP; Kwon JS
    Schizophr Res; 2009 Jun; 111(1-3):86-93. PubMed ID: 19406622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of metabotropic glutamate receptor-3 variants on prefrontal brain activity in schizophrenia: An imaging genetics study using multi-channel near-infrared spectroscopy.
    Kinoshita A; Takizawa R; Koike S; Satomura Y; Kawasaki S; Kawakubo Y; Marumo K; Tochigi M; Sasaki T; Nishimura Y; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():14-21. PubMed ID: 25914064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study.
    Sigmundsson T; Maier M; Toone BK; Williams SC; Simmons A; Greenwood K; Ron MA
    Schizophr Res; 2003 Nov; 64(1):63-71. PubMed ID: 14511802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dorsolateral prefrontal cortical pathology in generalized anxiety disorder: a proton magnetic resonance spectroscopic imaging study.
    Mathew SJ; Mao X; Coplan JD; Smith EL; Sackeim HA; Gorman JM; Shungu DC
    Am J Psychiatry; 2004 Jun; 161(6):1119-21. PubMed ID: 15169704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients.
    Sassi RB; Stanley JA; Axelson D; Brambilla P; Nicoletti MA; Keshavan MS; Ramos RT; Ryan N; Birmaher B; Soares JC
    Am J Psychiatry; 2005 Nov; 162(11):2109-15. PubMed ID: 16263851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between performance on the Stroop test and N-acetylaspartate in the medial prefrontal cortex in deficit and nondeficit schizophrenia: preliminary results.
    Delamillieure P; Constans JM; Fernandez J; Brazo P; Dollfus S
    Psychiatry Res; 2004 Nov; 132(1):87-9. PubMed ID: 15546706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia.
    Bertolino A; Knable MB; Saunders RC; Callicott JH; Kolachana B; Mattay VS; Bachevalier J; Frank JA; Egan M; Weinberger DR
    Biol Psychiatry; 1999 Mar; 45(6):660-7. PubMed ID: 10187995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabotropic glutamate receptor 3 is associated with heroin dependence but not depression or schizophrenia in a Chinese population.
    Jia W; Zhang R; Wu B; Dai ZX; Zhu YS; Li PP; Zhu F
    PLoS One; 2014; 9(1):e87247. PubMed ID: 24498053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.
    Bishop JR; Reilly JL; Harris MS; Patel SR; Kittles R; Badner JA; Prasad KM; Nimgaonkar VL; Keshavan MS; Sweeney JA
    Psychopharmacology (Berl); 2015 Jan; 232(1):145-54. PubMed ID: 25096017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia.
    Bishop JR; Miller del D; Ellingrod VL; Holman T
    Hum Psychopharmacol; 2011 Jan; 26(1):28-34. PubMed ID: 21344500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.
    Wood SJ; Berger GE; Lambert M; Conus P; Velakoulis D; Stuart GW; Desmond P; McGorry PD; Pantelis C
    Arch Gen Psychiatry; 2006 Sep; 63(9):969-76. PubMed ID: 16952999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.